Liquid Biopsy Market Revenues Are Projected to Expand at a CAGR of 21.7% During the Forecast Period 2016-2026
The minimally-invasive nature and economical affordability of liquid biopsy tests will play a key role in bolstering demand globally. FDA approvals for non-invasive diagnostic tests for cancers is expected to have a positive influence on the growth of the market.
View full press release